in vivo efficacy
The efficacy of the antibody in vivo was proven by intravenous (i.v.) delivery of TDP-O9 antibody in a short period of time in two ALS mouse models (at 9-10 month &13-15 month of age). The administration significantly increased motor neuron survival, improved motor behaviors, reduced ALS disease-like pathology.
I.v. delivery of TDP-O9 antibody in aged TDP-43 Q331K transgenic mice ameliorated motor function impairment and increased motor neuron survival.